These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21756839)

  • 1. [Bright field in-situ hybridization for delineation of HER2 status in breast cancer].
    Li X; Yang X; Zhang W; Yang M; Huang LP
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):358-60. PubMed ID: 21756839
    [No Abstract]   [Full Text] [Related]  

  • 2. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
    Ying JM; Guo L; Liu XY; Qiu T; Lü N
    Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
    Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
    J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce F; Bufo P
    Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
    Gao FF; Dabbs DJ; Cooper KL; Bhargava R
    Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
    Gruver AM; Peerwani Z; Tubbs RR
    J Clin Pathol; 2010 Mar; 63(3):210-9. PubMed ID: 20203220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HER2 gene amplification assay: is CISH an alternative to FISH?].
    Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
    Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
    Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
    Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
    Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
    Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma.
    Tubbs R; Skacel M; Pettay J; Powell R; Myles J; Hicks D; Sreenan J; Roche P; Stoler MH; Hainfeld J
    Am J Surg Pathol; 2002 Jul; 26(7):908-13. PubMed ID: 12131158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bright-field microscopy for HER2 gene assessment: not just DISH-ful thinking?
    Clark BZ; Bhargava R
    Am J Clin Pathol; 2013 Feb; 139(2):137-9. PubMed ID: 23355196
    [No Abstract]   [Full Text] [Related]  

  • 20. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.
    Bartlett JM; Campbell FM; Ibrahim M; Wencyk P; Ellis I; Kay E; Connolly Y; O'Grady A; Di Palma S; Starczynski J; Morgan JM; Jasani B; Miller K
    Am J Clin Pathol; 2009 Oct; 132(4):514-20. PubMed ID: 19762528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.